{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:11:20Z","timestamp":1788495080876,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":1842,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.seizure.2007.12.003","type":"journal-article","created":{"date-parts":[[2008,2,11]],"date-time":"2008-02-11T07:05:57Z","timestamp":1202713557000},"page":"405-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Central nervous system adverse effects of new antiepileptic drugs"],"prefix":"10.1016","volume":"17","author":[{"given":"G.","family":"Zaccara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.F.","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cincotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2007.12.003_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.wnf.0000159956.87511.67","article-title":"Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy","volume":"28","author":"Otoul","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2007.12.003_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1472-8206.2001.00055.x","article-title":"Clinical pharmacology and therapeutic use of the new antiepileptic drugs","volume":"15","author":"Perucca","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.seizure.2007.12.003_bib3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: asystematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0920-1211(01)00287-X","article-title":"Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review","volume":"46","author":"Marson","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2007.12.003_bib5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1528-1157.1999.tb05561.x","article-title":"New antiepileptic drugs: comparison of key clinical trials","volume":"40","author":"Cramer","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0920-1211(01)00286-8","article-title":"Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation","volume":"47","author":"Cramer","year":"2001","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2007.12.003_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0404.2002.02071.x","article-title":"Low-dose topiramate in adults with treatment-resistant partial-onset seizures","volume":"106","author":"Guberman","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2007.12.003_bib8","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/01.WNL.0000068024.20285.65","article-title":"Dose\u2013response trial of pregabalin adjunctive therapy in patients with partial seizures","volume":"60","author":"French","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2007.12.003_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","article-title":"Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose\u2013response study in adults with partial seizures","volume":"45","author":"Arroyo","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/01.WNL.0000150932.48688.BE","article-title":"Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy","volume":"64","author":"Beydoun","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2007.12.003_bib11","first-page":"31","article-title":"Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures","volume":"46","author":"Brodie","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib12","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1528-1167.2005.00341.x","article-title":"Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study","volume":"46","author":"Elger","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1440-1819.2006.01553.x","article-title":"Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study","volume":"60","author":"Yamauchi","year":"2006","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.seizure.2007.12.003_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2006.00372.x","article-title":"Efficacy and safety of levetiracetam (up to 2000mg\/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study","volume":"47","author":"Tsai","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1528-1157.1988.tb04236.x","article-title":"Adverse reactions to antiepileptic drugs: a follow-up study of 355 patients with chronic antiepileptic drug treatment","volume":"29","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00002018-200023010-00003","article-title":"Adverse reactions to new anticonvulsant drugs","volume":"23","author":"Wong","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.seizure.2007.12.003_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1684\/j.1950-6945.2004.tb00064.x","article-title":"Adverse motor effects induced by antiepileptic drugs","volume":"6","author":"Zaccara","year":"2004","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2007.12.003_bib18","unstructured":"Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2003."},{"key":"10.1016\/j.seizure.2007.12.003_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.seizure.2007.12.003_bib20","series-title":"Case-Control Studies","author":"Schlesselman","year":"1982"},{"key":"10.1016\/j.seizure.2007.12.003_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1991.tb04689.x","article-title":"Double-blind study of gabapentin in the treatment of partial seizures","volume":"32","author":"Sivenius","year":"1991","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib22","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1212\/WNL.43.11.2292","article-title":"Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2007.12.003_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1528-1157.1994.tb02513.x","article-title":"Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group","volume":"35","author":"Anhut","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0920-1211(96)00020-4","article-title":"Gabapentin in generalized seizures","volume":"25","author":"Chadwick","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2007.12.003_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1528-1157.1989.tb05309.x","article-title":"Controlled trial of lamotrigine for refractory partial seizures","volume":"30","author":"Jawad","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0920-1211(90)90099-H","article-title":"A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures","volume":"7","author":"Loiseau","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2007.12.003_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0920-1211(90)90077-9","article-title":"A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy","volume":"6","author":"Sander","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2007.12.003_bib28","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1212\/WNL.43.11.2284","article-title":"Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0. 5 Clinical Trial Group","volume":"43","author":"Matsuo","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2007.12.003_bib29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.56.5.448","article-title":"Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures","volume":"56","author":"Schapel","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.seizure.2007.12.003_bib30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1528-1157.1993.tb02417.x","article-title":"Outcomes of add-on treatment with lamotrigine in partial epilepsy","volume":"34","author":"Smith","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1528-1157.1994.tb02920.x","article-title":"Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial","volume":"35","author":"Messenheimer","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.1996.tb07060.x","article-title":"Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures","volume":"94","author":"Boas","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2007.12.003_bib33","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1528-1157.1998.tb01332.x","article-title":"Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy","volume":"39","author":"Beran","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2007.12.003_bib35","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2007.12.003_bib37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib38","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-1211(97)00082-X","article-title":"A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group","volume":"30","author":"Kalviainen","year":"1998","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2007.12.003_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-Menachem","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib41","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2007.12.003_bib42","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2007.12.003_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(96)00029-0","article-title":"Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy","volume":"25","author":"Sharief","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2007.12.003_bib44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1528-1157.1996.tb00649.x","article-title":"Double-blind, placebo-controlled trial of topiramate (600mg daily) for the treatment of refractory partial epilepsy","volume":"37","author":"Tassinari","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib45","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1528-1157.1999.tb01596.x","article-title":"Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial.","volume":"40","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib46","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1528-1157.2000.tb00321.x","article-title":"A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy","volume":"41","author":"Yen","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2007.12.003_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0920-1211(93)90011-U","article-title":"Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial","volume":"15","author":"Schmidt","year":"1993","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2007.12.003_bib48","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1212\/WNL.57.10.1774","article-title":"Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures","volume":"57","author":"Faught","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2007.12.003_bib49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.1997.00550170069016","article-title":"Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group","volume":"54","author":"Sachdeo","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1016\/j.seizure.2007.12.003_bib50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archneur.55.1.56","article-title":"Tiagabine for complex partial seizures: a randomized, add-on, dose\u2013response trial","volume":"55","author":"Uthman","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.seizure.2007.12.003_bib51","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1017\/S0317167100034867","article-title":"Using topiramate in patients with epilepsy: practical aspects","volume":"25","author":"Sander","year":"1998","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.seizure.2007.12.003_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2165\/00003495-199346010-00009","article-title":"Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2007.12.003_bib53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1056\/NEJM199002083220604","article-title":"Henobarbital for febrile seizures. Effects on intelligence and on seizure recurrence","volume":"322","author":"Farwell","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2007.12.003_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00002018-200023010-00003","article-title":"Adverse reactions to new anticonvulsant drugs","volume":"23","author":"Wong","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.seizure.2007.12.003_bib55","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2165\/00007256-200636100-00006","article-title":"Central fatigue: the serotonin hypothesis and beyond","volume":"36","author":"Meeusen","year":"2006","journal-title":"Sports Med"},{"key":"10.1016\/j.seizure.2007.12.003_bib56","series-title":"Antiepileptic Drugs","first-page":"335","article-title":"Gabapentin. Chemistry, biotransformation, pharmacokinetics, and interactions","author":"Vajda","year":"2002"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131107002609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131107002609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:36:24Z","timestamp":1761010584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131107002609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S1059131107002609"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2007.12.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central nervous system adverse effects of new antiepileptic drugs","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2007.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}